Molecular magnetic resonance imaging of myocardial perfusion with EP-3600, a collagen-specific contrast agent initial feasibility study in a swine model

Circulation

Volumn 119, Issue 13, 2009, Pages 1768-1775

  Spuentrup, Elmar ^a,b   Ruhl, Karl M ^a   Botnar, Rene M ^c   Wiethoff, Andrea J ^d   Buhl, Alexandra ^a   Jacques, Vincent ^e   Greenfield, Matthew T ^e   Krombach, Gabriele A ^a   Gunther, Rolf W ^a   Vangel, Mark G ^f   Caravan, Peter ^f  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d PHILIPS HEALTHCARE   (United States)

^e Epix Pharmaceuticals   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Contrast media; Coronary disease; Ischemia; Magnetic resonance imaging; Perfusion

Indexed keywords

COLLAGEN; CONTRAST MEDIUM; EP 3600; GADOLINIUM; PENTETIC ACID; UNCLASSIFIED DRUG; YTTERBIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; EP-3600; OLIGOPEPTIDE; ORGANOMETALLIC COMPOUND; YTTERBIUM DTPA;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BALLOON; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; FEASIBILITY STUDY; HEART ARRHYTHMIA; HEART MUSCLE; HEART PERFUSION; IMAGING; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIGNAL NOISE RATIO; STRESS; SWINE; ANIMAL; ARTIFACT; CHEMISTRY; CORONARY ARTERY BLOOD FLOW; DISEASE MODEL; EXTRACELLULAR SPACE; METABOLISM; METHODOLOGY; PATHOLOGY;

ANIMALS; ARTIFACTS; COLLAGEN; CONTRAST MEDIA; CORONARY CIRCULATION; CORONARY STENOSIS; DISEASE MODELS, ANIMAL; EXTRACELLULAR SPACE; FEASIBILITY STUDIES; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; OLIGOPEPTIDES; ORGANOMETALLIC COMPOUNDS; PENTETIC ACID; SUS SCROFA;

EID: 65349087970     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.826388     Document Type: Article

References (28)

1. Manning WJ, Atkinson DJ, Grossman W, Paulin S, Edelman RR. First-pass nuclear magnetic resonance imaging studies using gadolinium-DTPA in patients with coronary artery disease. J Am Coll Cardiol. 1991;18:959-965.
2. Wolff SD, Schwitter J, Coulden R, Friedrich MG, Bluemke DA, Biederman RW, Martin ET, Lansky AJ, Kashanian F, Foo TK, Licato PE, Comeau CR. Myocardial first-pass perfusion magnetic resonance imaging: a multicenter dose-ranging study. Circulation. 2004;110: 732-737.
3. Bertschinger KM, Nanz D, Buechi M, Luescher TF, Marincek B, von Schulthess GK, Schwitter J. Magnetic resonance myocardial first-pass perfusion imaging: parameter optimization for signal response and cardiac coverage. J Magn Reson Imaging. 2001;14:556-562.
4. Edelman RR, Li W. Contrast-enhanced echo-planar MR imaging of myocardial perfusion: preliminary study in humans. Radiology. 1994;190:771-777.
5. Eichenberger AC, Schuiki E, Kochli VD, Amann FW, McKinnon GC, von Schulthess GK. Ischemic heart disease: assessment with gadolinium- enhanced ultrafast MR imaging and dipyridamole stress. J Magn Reson Imaging. 1994;4:425-431.
6. Slavin GS, Wolff SD, Gupta SN, Foo TK. First-pass myocardial per- fusion MR imaging with interleaved notched saturation: feasibility study.Radiology. 2001;219:258-263.
7. Di Bella EV, Parker DL, Sinusas AJ. On the dark rim artifact in dynamic contrast-enhanced MRI myocardial perfusion studies. Magn Reson Med.2005;54:1295-1299.
8. Schwitter J, Nanz D, Kneifel S, Bertschinger K, Buchi M, Knusel PR,Marincek B, Luscher TF, von Schulthess GK. Assessment of myocardial perfusion in coronary artery disease by magnetic resonance: a comparison with positron emission tomography and coronary angiography. Circulation.2001;103:2230- 2235.
9. Nagel E, Klein C, Paetsch I, Hettwer S, Schnackenburg B, Wegscheider K, Fleck E. Magnetic resonance perfusion measurements for the nonin- vasive detection of coronary artery disease. Circulation. 2003;108:432-437.
10. Caravan P, Das B, Dumas S, Epstein FH, Helm PA, Jacques V, Koerner S, Kolodziej A, Shen L, Sun WC, Zhang Z. Collagen-targeted MRI contrast agent for molecular imaging of fibrosis. Angew Chem Int EdEngl. 2007;46:8171-8173.
11. Overoye-Chan K, Koerner S, Looby RJ, Kolodziej AF, Zech SG, Deng Q, Chasse JM, McMurry TJ, Caravan P. EP-2104R: a fibrin-specific gadolinium-based MRI contrast agent for detection of thrombus. JAmChem Soc. 2008;130:6025-6039.
12. Morcos SK, Thomsen HS. Nephrogenic systemic fibrosis: more questions and some answers. Nephron Clin Pract. 2008;110:c24-c32.
13. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS. Standardized myocardial segmentation and nomenclature for tomographic imaging of
14. the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539-542.
15. Kraitchman DL, Chin BB, Heldman AW, Solaiyappan M, Bluemke DA. MRI detection of myocardial perfusion defects due to coronary artery stenosis with MS-325. J Magn Reson Imaging. 2002;15:149 -158.
16. Schwitter J, Saeed M, Wendland MF, Sakuma H, Bremerich J, Canet E, Higgins CB. Assessment of myocardial function and perfusion in a canine model of non-occlusive coronary artery stenosis using fast magnetic resonance imaging. J Magn Reson Imaging. 1999;9:101-110.
17. Spuentrup E, Ruebben A, Schaeffter T, Manning WJ, Gunther RW, Buecker A. Magnetic resonance-guided coronary artery stent placement in a swine model. Circulation. 2002;105:874-879.
18. Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, Pohost GM, Rade- makers FE, van Rossum AC, Shaw LJ, Yucel EK. Clinical indications for cardiovascular magnetic resonance (CMR): consensus panel report. Eur Heart J. 2004;25:1940-1965.
19. Borg TK, Caulfield JB. The collagen matrix of the heart. Fed Proc. 1981;40:2037-2041.
20. Jugdutt BI. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation. 2003;108: 1395-1403.
21. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715-724.
22. Helm PA, Caravan P, French BA, Jacques V, Shen L, Xu Y, Beyers RJ, Roy RJ, Kramer CM, Epstein FH. Postinfarction myocardial scarring in mice: molecular MR imaging with use of a collagen-targeting contrast agent. Radiology. 2008;247:788-796.
23. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn JP, Klocke FJ, Judd RM. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100:1992-2002.
24. Wilke N, Kroll K, Merkle H, Wang Y, Ishibashi Y, Xu Y, Zhang J, Jerosch-Herold M, Muhler A, Stillman AE, Bassingthwaighte JB, Bache R, Ugurbil K. Regional myocardial blood volume and flow: first-pass MR imaging with polylysine-Gd-DTPA. J Magn Reson Imaging. 1995;5: 227-237.
25. Bjerner T, Johansson L, Ericsson A, Wikstrom G, Hemmingsson A, Ahlstrom H. First-pass myocardial perfusion MR imaging with outer- volume suppression and the intravascular contrast agent NC100150 injection: preliminary results in eight patients. Radiology. 2001;221:822-826.
26. Gerber BL, Bluemke DA, Chin BB, Boston RC, Heldman AW, Lima JA, Kraitchman DL. Single-vessel coronary artery stenosis: myocardial per- fusion imaging with Gadomer-17 first-pass MR imaging in a swine model of comparison with gadopentetate dimeglumine. Radiology. 2002;225:104 -112.
27. Storey P, Danias PG, Post M, Li W, Seoane PR, Harnish PP, Edelman RR, Prasad PV. Preliminary evaluation of EVP 1001-1: a new cardiac- specific magnetic resonance contrast agent with kinetics suitable for steady-state imaging of the ischemic heart. Invest Radiol. 2003;38:642-652.
28. Friedrich MG, Niendorf T, Schulz-Menger J, Gross CM, Dietz R. Bloodoxygen level-dependent magnetic resonance imaging in patients with stress-induced angina. Circulation. 2003;108:2219-2223.